Status:
COMPLETED
Pharmacodynamic Effects of Cangrelor in ACS or CCS Patients Undergoing PCI (POMPEII Registry)
Lead Sponsor:
Federico II University
Conditions:
Percutaneous Coronary Intervention
Eligibility:
All Genders
18+ years
Brief Summary
This prospective registry was designed to carefully investigate the pharmacodynamic (PD) effects of cangrelor in all patients undergoing percutaneous coronary intervention (PCI).
Detailed Description
There is huge interest in achieving fast and immediate antiplatelet effect at the time of PCI, particularly in acute myocardial infarction and Cangrelor is an intravenous antagonist of the P2Y12 recep...
Eligibility Criteria
Inclusion
- All adult patients undergoing PCI and receiving cangrelor administration will be eligible for inclusion in the study.
Exclusion
- only those not providing consent to blood/data collection will be excluded.
Key Trial Info
Start Date :
March 16 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2024
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04790032
Start Date
March 16 2021
End Date
July 1 2024
Last Update
August 7 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Federico II of Naples
Napoli, Italy, 80131